About us

Our vision

At the heart of Ad Scientiam’s project is a conviction: continuously measuring and following the evolution of severe and disabling diseases in real life is the key to better care for patients.

 

 

Ad Scientiam is taking this scientific and technological bet, so that today each patient can be an actor in their own health and to accelerate the development of new treatments.

 

We are committed to ensuring that the medicine of tomorrow is more predictive, preventive and individualized.

We make it the foundation of our activity.

Our contribution

Hitherto undetectable, these evolutions are now visible through the design and clinical validation of digital biomarkers. These are derived from data continuously collected via a digital tool, such as the patient's smartphone for example, and transformed by proprietary algorithms.

 

Their use allows Ad Scientiam to provide innovative, easy-to-use and intuitive solutions for:

Help patients

Help them to measure in real life the evolution of their health and facilitate clinical decision-making by healthcare professionals.

Accelerate drug development

Accelerate drug development by deploying new criteria for evaluating their efficacy.

Reduce the societal and economic impact

Reduce the societal and economic impact of diseases through new care pathways for patients.

Our values

We want to be useful, starting today, to the greatest number of patients. For them, as a pioneer in digital biomarkers, we have set ourselves ambitious objectives, which we are pursuing relentlessly.

 

1

Usefulness

2

Quickness

Our obsession is to get results quickly, because our scientific and technological advances only make sense if they are shared widely and rapidly.

We do this without compromising on the security and confidentiality of the health data entrusted to us.

3

Security & confidentiality

Every day, we combine our expertise with our agility to create an inclusive environment, fostering innovation and thus passionately support our mission to serve patients.

Our team

Ad Scientiam réunit une équipe passionnée d’innovation digitale en santé, qui compte plus de 70 personnes aujourd’hui.

Mobile development, UX / UI, Clinical Research, Data Science, Product, we put the diversity of our skills and our creativity at the service of the patient.

Do you want to know more about our professions? Find testimonials from :

  • Alexandre (Data Scientist)
  • Charline (Cheffe de projet affaires médicales) 
  • Ivan (Responsable d’équipe)
  • Séverine (Responsable des évaluations cliniques)

Matthieu Lamy

President
Consult profile

Matthieu graduated from HEC Paris. For nearly ten years, he advised large international groups on the implementation of reorganization, digital transformation and startup acceleration projects. He joined Ad Scientiam at the end of 2016 to accelerate and structure the development of the company in the United States. Returning to France in the summer of 2020, he gradually took over the executive functions of the company, first as Chief Executive Officer, and, since October 2021, as President of Ad Scientiam.

Saad Zinaï

Chief medical officer
Consult profile

Saad is a physician and holds an MBA from ESCP Europe. After clinical experience in radiology (Charles-Foix, Pierre and Marie Curie University), he spent 25 years in multinational pharmaceutical companies where he took on marketing, medical and commercial responsibilities. In his last position at Recordati France, he set up the addiction business unit and successfully launched several treatments in hypertension, migraine, allergy, urology, OTC and generics. He joined Ad Scientiam in 2016 where he took charge of scientific and medical activities.

Térence Brochu

Chief eXperience Officer

Térence has a background in cognitive psychology, neuropsychology, ergonomics and UX design. Co-founder of Ad Scientiam, he ensures a user centered approach by integrating patient and clinician insights through the design process of Ad Scientiam solutions.

François de Berry

Heaf of software engineering

Expert in computer sciences, graduated at EPITECH, François quickly specialized in mobile technologies. Since 2013, he is in charge of the development and evolution of innovative mobile solutions developed by Ad Scientiam.

Séverine Bieuvelet

Head of Clinical Research

Séverine holds a PhD in Physiology and Physiopathology, graduated from the University of Paris 6. She worked for more than 15 years in clinical research in private and public laboratories on phase III and IV studies and joined Ad Scientiam at the end of 2016. She is in charge of the clinical research department and the conduct of pre- and post-marketing clinical evaluation for mobile applications developed by Ad Scientiam in compliance with regulations.

Loïc Carment

Chief Data Officer

Loïc holds a PhD in Neuroscience, a graduate of Pierre and Marie Curie University, Paris VI. Before Ad Scientiam, Loïc was a post-doctoral researcher in an INSERM laboratory and he brings his experience and rigor to understanding scientific and clinical needs. Loïc heads the data division at Ad Scientiam (Data Science, Data Management, Biostatistics). He is responsible for defining and implementing the company's Data strategy, and supporting the development, validation and implementation of digital biomarkers obtained through our software medical devices.

Clarissa Gorin

Head of Medical Innovation

Clarissa has a PhD in Pharmacy, with a double degree in Pharmaceutical Management and Biotechnology from ESCP Business school. Passionate about new technologies and their applications in the health sector, she has a first experience in a startup specializing in blockchain. She joined Ad Scientiam in 2020 as Head of Medical Innovation. This pole is in charge of defining the medical need during the framing phases, in collaboration with patients, patient associations and healthcare professionals in order to conceptualize the new digital solutions of Ad Scientiam.

Bastien Ricono

Head of Product

Bastien is a graduate engineer from ENSIIE. After working for various companies in technical and project management positions, he turned to Product in 2017. Having always been interested in medicine and data, he then joined Ad Scientiam in early 2023 as Head of Product. 

Hadrien Oger

Responsable Juridique - Délégué à la Protection des Données

Titulaire d’un Master 2 en Droit des affaires de l’Université Paris II Panthéon-Assas, Hadrien accompagne Ad Scientiam depuis 2018 en tant que Responsable Juridique. Son rôle consiste à guider Ad Scientiam dans la mise en place de partenariats commerciaux et dans le développement de ses activités, tant à l’échelle nationale qu’internationale. Il contribue ainsi activement à la protection de la propriété intellectuelle et des intérêts de l’entreprise. En qualité de Délégué à la Protection des Données, Hadrien veille également à la conformité des activités d’Ad Scientiam avec les réglementations sur le traitement des données personnelles.

Assia El Arrassi

Responsable des affaires réglementaires

Assia est titulaire d’un Master Biologie et Santé. Passionnée par les dispositifs médicaux, elle a acquis une première expérience en qualité et affaires réglementaires au sein d’une société spécialisée dans les dispositifs implantables consommables. En 2022, elle rejoint Ad Scientiam en tant que Responsable des Affaires Réglementaires. Dans ce rôle, elle est chargée de définir et mettre en œuvre les stratégies réglementaires, assurant ainsi la conformité des produits de l’entreprise avec les normes et réglementations en vigueur.

Awards and Selections

AdScientiam x Merck KGaA: a collaboration to innovate in gMG care Read the article
en_USEnglish